Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.

BioInvent International

Ylin-
Alin-
Vaihto-
2026 Q3 - tulosraportti
21 päivää sitten

Tarjoustasot

Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMäärä
80
302
120
320
248

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Rahastoja ja ETF:iä jotka omistavat osaketta

Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q4 - tulosraportti
25.2.2027
Menneet tapahtumat
2026 Q3 - tulosraportti
29.10.
2026 Q2 - tulosraportti
27.8.
2026 Q1 - tulosraportti
29.4.
2025 Q4 - tulosraportti
26.2.
2025 Q3 - tulosraportti
29.10.2025

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Foorumi

Liity keskusteluun Nordnet Socialissa
  • Käyttäjän profiilikuva
    22 t sitten
    ·
    This reminds me of my loss in ISR. Do not own any Bioinvent myself but advise against giving more money to management. Know that it stings properly but sometimes you need a slap in the face to wake up
  • Käyttäjän profiilikuva
    2 päivää sitten
    ·
    496 million shares. E With a future price of 3 kr per share, the company would be valued at approx. 1.5 billion. Is that reasonable?
    Käyttäjän profiilikuva
    2 päivää sitten
    ·
    But maybe reasonable with a share price of 2 kronor and a company valuation of 1 billion after the emission. In that case a good profit for those who now buy in for 1 krona/share. Especially if positive news then comes for any of their candidates. Then you get several 100 % in a short time. Very sad for existing owners. Seems to be a robbery.
  • Käyttäjän profiilikuva
    11.11. · Muokattu
    ·
    The company even openly admits that it was agreed with the underwriters that share prices should first be beaten down before setting the incredibly low price that the underwriters can get the share for at the expense of current shareholders. "Cecilia Hofvander comments: "We understand that the issue announcement without final terms created uncertainty and that the share price was affected. The setup was a conscious choice negotiated with the underwriters" Clip from https://www.affarsvarlden.se/artikel/bioinvents-nyemission-tre-flaggor-efter-kursslakten Emissionsguiden raises three flags. Large discount (initially) A large discount in a directed issue is a clear warning sign. But even in a rights issue, it shows great reluctance from underwriters and/or existing major shareholders to step up. The subscription price of 1 kr per share implies a discount of a staggering 73% against TERP. The discount is calculated on the ten-day volume-weighted average price before the company announced the issue. Bioinvent's Head of IR Cecilia Hofvander comments: "Since the issue was announced before the terms were known, the share price had already priced in the issue when the subscription price was set. A reference price based on 10-day VWAP before the initial announcement therefore yields a heavily exaggerated discount, as it is based on a price that no longer applied. Market practice is to measure the discount against the last traded price prior to the publication of the terms, and otherwise, apples are not compared with apples." When assessing a discount, Emissionsguiden always bases it on the date the companies notify the market of the upcoming issue. This also applies in cases where the terms are published only later, which Bioinvent did. Basing it on the later date would give these companies an advantage, as the assessment would then completely ignore the initial decline. High issue cost If one knows or has good reason to assume that the cost of advisors, underwriters, etc., eats up a large part of the issue proceeds, this is bad in several ways. However, the bar is set very differently depending on whether it is 10 MSEK or 1 billion to be raised. Bioinvent expects net proceeds of 366 MSEK, which implies issue costs of approximately 62 MSEK. This corresponds to 14.5% of the issue amount. In an issue of this size, that is high enough for a flag to be raised. Bioinvent refers to the fact that an underwriting fee of 12% is in line with comparable transactions, for example Orexo (13%) and Scandinavian Enviro (12%). Emissionsguiden's assessment, however, does not take into account what the costs consist of. Having to pay 62 MSEK to raise 428 MSEK is worth a flag, regardless of whether it is underwriters or something else driving up costs. The underwriting fee in Bioinvent's issue corresponds to approximately 42 MSEK. Messy issue process A messy process can indicate problems behind the scenes or poor planning. Examples of a messy issue process can be changed timetables, sudden management changes, late-entered investment commitments, or issue announcements without issue terms. Bioinvent announced the issue on October 28, but the final terms only arrived on November 5. Announcing an issue without a subscription price and other central terms leaves investors in uncertainty and often entails weak price performance. The share plummeted 72% on the first trading day after the issue announcement. Then it fell another 35% during the week when the market awaited the final terms. The underwriting commitments were expanded by 78 MSEK (an increase of 29%) when the issue terms were presented. The underwriting fee was simultaneously raised from 11 to 12% on the entire guarantee amount. Bioinvent also deviated from the original timetable. The terms were initially expected to be presented around November 25. Cecilia Hofvander comments: "We understand that the issue announcement without final terms created uncertainty and that the share price was affected. The setup was a conscious choice negotiated with the underwriters, so that the terms would reflect the share price taking into account the issue announcement when the shareholders make their decision. After the announcement, the market reacted and the board's assessment is that the information has been absorbed by the market, which enabled an earlier announcement of terms." The subscription period runs from December 7-21. Emissionsguiden will likely return with a new article around the time the company publishes its information document around December 2. Otherwise, the next article will be in connection with the outcome.
    Käyttäjän profiilikuva
    1 päivä sitten
    ·
    Perhaps reasonable with a share price of 2 kronor and a company valuation of 1 billion after the issue. In that case a good profit for those who are now buying in for 1 krona/share. Especially if positive news then comes for one of their candidates. Then you get several 100 % in a short time. Very sad for existing owners. Seems to be a robbery.
  • Käyttäjän profiilikuva
    9.11.
    ·
    As said, the share price will find its way up to around 6-7 kr before the date for trading in TR begins
    Käyttäjän profiilikuva
    10.11.
    ·
    Don't know what you are basing this on, but hope you are really right.
  • Käyttäjän profiilikuva
    8.11.
    ·
    For only 6 months ago the share price was 34ish and now the share price is at 2.49 and soon at price 1ish. It ought to almost be illegal to have such amateurish management. It takes a split second to lose credibility but on the other hand it takes a long time to rebuild. This issue can impossibly leave any sensible individuals who have faith in this management.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Välittäjätilasto

Ostaneet eniten

Ostaneet eniten
VälittäjäOstettuMyytyNettoSisäinen
Anonyymi575 409575 40900

Myyneet eniten

Myyneet eniten
VälittäjäOstettuMyytyNettoSisäinen
Anonyymi575 409575 40900
2026 Q3 - tulosraportti
21 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Foorumi

Liity keskusteluun Nordnet Socialissa
  • Käyttäjän profiilikuva
    22 t sitten
    ·
    This reminds me of my loss in ISR. Do not own any Bioinvent myself but advise against giving more money to management. Know that it stings properly but sometimes you need a slap in the face to wake up
  • Käyttäjän profiilikuva
    2 päivää sitten
    ·
    496 million shares. E With a future price of 3 kr per share, the company would be valued at approx. 1.5 billion. Is that reasonable?
    Käyttäjän profiilikuva
    2 päivää sitten
    ·
    But maybe reasonable with a share price of 2 kronor and a company valuation of 1 billion after the emission. In that case a good profit for those who now buy in for 1 krona/share. Especially if positive news then comes for any of their candidates. Then you get several 100 % in a short time. Very sad for existing owners. Seems to be a robbery.
  • Käyttäjän profiilikuva
    11.11. · Muokattu
    ·
    The company even openly admits that it was agreed with the underwriters that share prices should first be beaten down before setting the incredibly low price that the underwriters can get the share for at the expense of current shareholders. "Cecilia Hofvander comments: "We understand that the issue announcement without final terms created uncertainty and that the share price was affected. The setup was a conscious choice negotiated with the underwriters" Clip from https://www.affarsvarlden.se/artikel/bioinvents-nyemission-tre-flaggor-efter-kursslakten Emissionsguiden raises three flags. Large discount (initially) A large discount in a directed issue is a clear warning sign. But even in a rights issue, it shows great reluctance from underwriters and/or existing major shareholders to step up. The subscription price of 1 kr per share implies a discount of a staggering 73% against TERP. The discount is calculated on the ten-day volume-weighted average price before the company announced the issue. Bioinvent's Head of IR Cecilia Hofvander comments: "Since the issue was announced before the terms were known, the share price had already priced in the issue when the subscription price was set. A reference price based on 10-day VWAP before the initial announcement therefore yields a heavily exaggerated discount, as it is based on a price that no longer applied. Market practice is to measure the discount against the last traded price prior to the publication of the terms, and otherwise, apples are not compared with apples." When assessing a discount, Emissionsguiden always bases it on the date the companies notify the market of the upcoming issue. This also applies in cases where the terms are published only later, which Bioinvent did. Basing it on the later date would give these companies an advantage, as the assessment would then completely ignore the initial decline. High issue cost If one knows or has good reason to assume that the cost of advisors, underwriters, etc., eats up a large part of the issue proceeds, this is bad in several ways. However, the bar is set very differently depending on whether it is 10 MSEK or 1 billion to be raised. Bioinvent expects net proceeds of 366 MSEK, which implies issue costs of approximately 62 MSEK. This corresponds to 14.5% of the issue amount. In an issue of this size, that is high enough for a flag to be raised. Bioinvent refers to the fact that an underwriting fee of 12% is in line with comparable transactions, for example Orexo (13%) and Scandinavian Enviro (12%). Emissionsguiden's assessment, however, does not take into account what the costs consist of. Having to pay 62 MSEK to raise 428 MSEK is worth a flag, regardless of whether it is underwriters or something else driving up costs. The underwriting fee in Bioinvent's issue corresponds to approximately 42 MSEK. Messy issue process A messy process can indicate problems behind the scenes or poor planning. Examples of a messy issue process can be changed timetables, sudden management changes, late-entered investment commitments, or issue announcements without issue terms. Bioinvent announced the issue on October 28, but the final terms only arrived on November 5. Announcing an issue without a subscription price and other central terms leaves investors in uncertainty and often entails weak price performance. The share plummeted 72% on the first trading day after the issue announcement. Then it fell another 35% during the week when the market awaited the final terms. The underwriting commitments were expanded by 78 MSEK (an increase of 29%) when the issue terms were presented. The underwriting fee was simultaneously raised from 11 to 12% on the entire guarantee amount. Bioinvent also deviated from the original timetable. The terms were initially expected to be presented around November 25. Cecilia Hofvander comments: "We understand that the issue announcement without final terms created uncertainty and that the share price was affected. The setup was a conscious choice negotiated with the underwriters, so that the terms would reflect the share price taking into account the issue announcement when the shareholders make their decision. After the announcement, the market reacted and the board's assessment is that the information has been absorbed by the market, which enabled an earlier announcement of terms." The subscription period runs from December 7-21. Emissionsguiden will likely return with a new article around the time the company publishes its information document around December 2. Otherwise, the next article will be in connection with the outcome.
    Käyttäjän profiilikuva
    1 päivä sitten
    ·
    Perhaps reasonable with a share price of 2 kronor and a company valuation of 1 billion after the issue. In that case a good profit for those who are now buying in for 1 krona/share. Especially if positive news then comes for one of their candidates. Then you get several 100 % in a short time. Very sad for existing owners. Seems to be a robbery.
  • Käyttäjän profiilikuva
    9.11.
    ·
    As said, the share price will find its way up to around 6-7 kr before the date for trading in TR begins
    Käyttäjän profiilikuva
    10.11.
    ·
    Don't know what you are basing this on, but hope you are really right.
  • Käyttäjän profiilikuva
    8.11.
    ·
    For only 6 months ago the share price was 34ish and now the share price is at 2.49 and soon at price 1ish. It ought to almost be illegal to have such amateurish management. It takes a split second to lose credibility but on the other hand it takes a long time to rebuild. This issue can impossibly leave any sensible individuals who have faith in this management.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMäärä
80
302
120
320
248

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Rahastoja ja ETF:iä jotka omistavat osaketta

Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q4 - tulosraportti
25.2.2027
Menneet tapahtumat
2026 Q3 - tulosraportti
29.10.
2026 Q2 - tulosraportti
27.8.
2026 Q1 - tulosraportti
29.4.
2025 Q4 - tulosraportti
26.2.
2025 Q3 - tulosraportti
29.10.2025

Välittäjätilasto

Ostaneet eniten

Ostaneet eniten
VälittäjäOstettuMyytyNettoSisäinen
Anonyymi575 409575 40900

Myyneet eniten

Myyneet eniten
VälittäjäOstettuMyytyNettoSisäinen
Anonyymi575 409575 40900
2026 Q3 - tulosraportti
21 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q4 - tulosraportti
25.2.2027
Menneet tapahtumat
2026 Q3 - tulosraportti
29.10.
2026 Q2 - tulosraportti
27.8.
2026 Q1 - tulosraportti
29.4.
2025 Q4 - tulosraportti
26.2.
2025 Q3 - tulosraportti
29.10.2025

Foorumi

Liity keskusteluun Nordnet Socialissa
  • Käyttäjän profiilikuva
    22 t sitten
    ·
    This reminds me of my loss in ISR. Do not own any Bioinvent myself but advise against giving more money to management. Know that it stings properly but sometimes you need a slap in the face to wake up
  • Käyttäjän profiilikuva
    2 päivää sitten
    ·
    496 million shares. E With a future price of 3 kr per share, the company would be valued at approx. 1.5 billion. Is that reasonable?
    Käyttäjän profiilikuva
    2 päivää sitten
    ·
    But maybe reasonable with a share price of 2 kronor and a company valuation of 1 billion after the emission. In that case a good profit for those who now buy in for 1 krona/share. Especially if positive news then comes for any of their candidates. Then you get several 100 % in a short time. Very sad for existing owners. Seems to be a robbery.
  • Käyttäjän profiilikuva
    11.11. · Muokattu
    ·
    The company even openly admits that it was agreed with the underwriters that share prices should first be beaten down before setting the incredibly low price that the underwriters can get the share for at the expense of current shareholders. "Cecilia Hofvander comments: "We understand that the issue announcement without final terms created uncertainty and that the share price was affected. The setup was a conscious choice negotiated with the underwriters" Clip from https://www.affarsvarlden.se/artikel/bioinvents-nyemission-tre-flaggor-efter-kursslakten Emissionsguiden raises three flags. Large discount (initially) A large discount in a directed issue is a clear warning sign. But even in a rights issue, it shows great reluctance from underwriters and/or existing major shareholders to step up. The subscription price of 1 kr per share implies a discount of a staggering 73% against TERP. The discount is calculated on the ten-day volume-weighted average price before the company announced the issue. Bioinvent's Head of IR Cecilia Hofvander comments: "Since the issue was announced before the terms were known, the share price had already priced in the issue when the subscription price was set. A reference price based on 10-day VWAP before the initial announcement therefore yields a heavily exaggerated discount, as it is based on a price that no longer applied. Market practice is to measure the discount against the last traded price prior to the publication of the terms, and otherwise, apples are not compared with apples." When assessing a discount, Emissionsguiden always bases it on the date the companies notify the market of the upcoming issue. This also applies in cases where the terms are published only later, which Bioinvent did. Basing it on the later date would give these companies an advantage, as the assessment would then completely ignore the initial decline. High issue cost If one knows or has good reason to assume that the cost of advisors, underwriters, etc., eats up a large part of the issue proceeds, this is bad in several ways. However, the bar is set very differently depending on whether it is 10 MSEK or 1 billion to be raised. Bioinvent expects net proceeds of 366 MSEK, which implies issue costs of approximately 62 MSEK. This corresponds to 14.5% of the issue amount. In an issue of this size, that is high enough for a flag to be raised. Bioinvent refers to the fact that an underwriting fee of 12% is in line with comparable transactions, for example Orexo (13%) and Scandinavian Enviro (12%). Emissionsguiden's assessment, however, does not take into account what the costs consist of. Having to pay 62 MSEK to raise 428 MSEK is worth a flag, regardless of whether it is underwriters or something else driving up costs. The underwriting fee in Bioinvent's issue corresponds to approximately 42 MSEK. Messy issue process A messy process can indicate problems behind the scenes or poor planning. Examples of a messy issue process can be changed timetables, sudden management changes, late-entered investment commitments, or issue announcements without issue terms. Bioinvent announced the issue on October 28, but the final terms only arrived on November 5. Announcing an issue without a subscription price and other central terms leaves investors in uncertainty and often entails weak price performance. The share plummeted 72% on the first trading day after the issue announcement. Then it fell another 35% during the week when the market awaited the final terms. The underwriting commitments were expanded by 78 MSEK (an increase of 29%) when the issue terms were presented. The underwriting fee was simultaneously raised from 11 to 12% on the entire guarantee amount. Bioinvent also deviated from the original timetable. The terms were initially expected to be presented around November 25. Cecilia Hofvander comments: "We understand that the issue announcement without final terms created uncertainty and that the share price was affected. The setup was a conscious choice negotiated with the underwriters, so that the terms would reflect the share price taking into account the issue announcement when the shareholders make their decision. After the announcement, the market reacted and the board's assessment is that the information has been absorbed by the market, which enabled an earlier announcement of terms." The subscription period runs from December 7-21. Emissionsguiden will likely return with a new article around the time the company publishes its information document around December 2. Otherwise, the next article will be in connection with the outcome.
    Käyttäjän profiilikuva
    1 päivä sitten
    ·
    Perhaps reasonable with a share price of 2 kronor and a company valuation of 1 billion after the issue. In that case a good profit for those who are now buying in for 1 krona/share. Especially if positive news then comes for one of their candidates. Then you get several 100 % in a short time. Very sad for existing owners. Seems to be a robbery.
  • Käyttäjän profiilikuva
    9.11.
    ·
    As said, the share price will find its way up to around 6-7 kr before the date for trading in TR begins
    Käyttäjän profiilikuva
    10.11.
    ·
    Don't know what you are basing this on, but hope you are really right.
  • Käyttäjän profiilikuva
    8.11.
    ·
    For only 6 months ago the share price was 34ish and now the share price is at 2.49 and soon at price 1ish. It ought to almost be illegal to have such amateurish management. It takes a split second to lose credibility but on the other hand it takes a long time to rebuild. This issue can impossibly leave any sensible individuals who have faith in this management.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMäärä
80
302
120
320
248

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Rahastoja ja ETF:iä jotka omistavat osaketta

Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.

Välittäjätilasto

Ostaneet eniten

Ostaneet eniten
VälittäjäOstettuMyytyNettoSisäinen
Anonyymi575 409575 40900

Myyneet eniten

Myyneet eniten
VälittäjäOstettuMyytyNettoSisäinen
Anonyymi575 409575 40900
© 2026 Nordnet Bank AB.
Nordnet | Alvar Aallon katu 5 C, 3. krs | FI-00100 Helsinki